Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02684162
Recruitment Status : Recruiting
First Posted : February 17, 2016
Last Update Posted : December 4, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:
This phase IIa trial studies how well guadecitabine works in treating patients with acute myelogenous leukemia and myelodysplastic syndrome that has returned after a period of improvement after allogeneic stem cell transplant. Guadecitabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Giving guadecitabine before the transplant may stop this from happening. Once the donated stem cells begin working, the patient's immune system may see the remaining cancer cells as not belonging in the patient's body and destroy them. Giving an infusion of the donor's white blood cells (donor lymphocyte infusion) may boost this effect.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia High Risk Acute Myeloid Leukemia High Risk Myelodysplastic Syndrome Minimal Residual Disease Myelodysplastic Syndrome Recurrent Acute Myeloid Leukemia Recurrent Myelodysplastic Syndrome Biological: Donor Lymphocytes Drug: Guadecitabine Other: Laboratory Biomarker Analysis Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. To determine the complete response (CR) rate of guadecitabine (SGI-110) with or without donor lymphocyte infusion (DLI) either for the treatment of morphologic relapse or the presence of minimal residual disease (MRD) in patients with acute myeloid leukemia or myelodysplastic syndrome after hematopoietic stem cell transplantation in patients with AML and MDS (cohort 1 and 2).

II. The relapse-free survival with the use of SGI-110 as maintenance therapy in patients with high risk acute myeloid leukemia or myelodysplastic syndrome after hematopoietic stem cell transplantation (cohort 3).

SECONDARY OBJECTIVES:

I. To determine the safety and toxicity of SGI-110 with or without DLI in this subject population.

II. To evaluate overall response and survival.

OUTLINE:

Patients receive guadecitabine subcutaneously (SC) once daily (QD) on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive DLI intravenously (IV) over 10-30 minutes on day 6 of cycles 2, 4, and 6 in the absence of disease progression or unacceptable toxicity.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial to Assess the Efficacy and Toxicity of SGI-110 With DLI for the Treatment of AML or MDS Relapsing After Allogeneic Stem Cell Transplantation
Actual Study Start Date : June 22, 2016
Estimated Primary Completion Date : June 30, 2021
Estimated Study Completion Date : June 30, 2021


Arm Intervention/treatment
Experimental: Treatment (guadecitabine, DLI)
Patients receive guadecitabine SC QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive DLI IV over 10-30 minutes on day 6 of cycles 2, 4, and 6 in the absence of disease progression or unacceptable toxicity.
Biological: Donor Lymphocytes
Given IV

Drug: Guadecitabine
Given SC
Other Names:
  • DNMT inhibitor SGI-110
  • S110
  • SGI-110

Other: Laboratory Biomarker Analysis
Correlative studies




Primary Outcome Measures :
  1. Complete response (CR) rate (Cohort 1 and 2) [ Time Frame: After enrollment ]
    Up to 12 courses

  2. Relapse free survival (RFS) (Cohort 3) [ Time Frame: Up to 1 year ]
    The Bayesian method of Thall et al will be used to monitor RFS time in this cohort.


Secondary Outcome Measures :
  1. Incidence of hematologic and non-hematologic toxicity [ Time Frame: Assessed up to 4 courses (16 weeks) ]
    Using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Will be tabulated within each subgroup (minimal residual disease and relapsed).

  2. Overall response rate [ Time Frame: Up to 12 courses (48 weeks) ]
  3. Duration of remission [ Time Frame: Duration of time from start of treatment to time of remission, assessed up to 12 courses (48 weeks) ]
  4. Incidence of acute graft versus host disease (GVHD) [ Time Frame: Up to day 6 of second course of guadecitabine (day 34) ]
  5. Incidence of chronic GVHD [ Time Frame: Up to 12 courses (48 weeks) ]
  6. Overall survival (OS) [ Time Frame: At 1 year ]
    Within each treatment cohorts, these events will be tabulated and the distributions of OS time estimated using the method of Kaplan and Meier.

  7. Disease-free survival time (DFS) [ Time Frame: At 1 year ]
    Within each treatment cohorts, these events will be tabulated and the distributions of DFS time estimated using the method of Kaplan and Meier.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of AML and MDS according to World Health Organization (WHO) classification that underwent first allogeneic hematopoietic cell transplant (HSCT) with either peripheral blood or bone marrow as the source of the hematopoietic stem cells
  • No more than 1 antigen mismatch at human leukocyte antigen (HLA)-A, B, C, DRB1 and DQB1 locus for either related or unrelated donor
  • High risk AML and MDS patients will be included; cohort 1: morphological relapse after stem cell transplant:

    • MDS patients: re-appearance of dysplastic changes in the bone marrow, with or without increase in bone marrow last count, which is pathologically consistent with myelodysplastic syndrome;
    • AML patients: bone marrow blast count >= 5%
  • Cohort 2: Persistence or reappearance of minimal residual disease by flow cytometry or cytogenetic or molecular testing while being in morphological remission after allogeneic stem cell transplantation
  • Cohort 3: High risk AML and MDS patients who are in complete remission morphologically with no evidence of minimal residual disease by flow cytometry or cytogenetic or molecular testing after allogeneic stem cell transplantation
  • MDS patients:

    • Cytogenetics consistent with poor or very poor risk group by 5-risk classification;
    • Cytogenetics consistent with monosomal karyotype
    • Bone marrow blast count > 5% but less than 20% at any time during their disease course before HSCT
    • Peripheral blood blast =< 5% at HSCT
    • Therapy-related MDS
  • AML patients:

    • Cytogenetics and molecular features consistent with adverse risk group;
    • Presence of minimal residual disease by multi-color flow cytometry or cytogenetics or molecular studies at the time of HSCT;
    • Presence of active disease defined as bone marrow blast count > 5% but less than =< 10% at the time of HSCT
    • Peripheral blood blast count =< 5% at HSCT
    • Therapy-related AML
  • Be able to start the drug therapy between 42 to 100 days following allogeneic SCT;

    • No more than 1 prior allogeneic SCT
    • Post-transplant bone marrow consistent with complete remission with no evidence of minimal residual disease by flow-cytometry or cytogenetics or molecular testing
    • Adequate engraftment within 14 days prior to starting study drug: absolute neutrophil count (ANC) >= 1.0 x 10^9/L without daily use of myeloid growth factor; and, platelet >= 50 x 10^9/L without platelet transfusion within 1 week
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
  • Serum creatinine =< 1.5 mg/dL or creatinine clearance greater or equal than 40 cc/min as defined by the Cockcroft-Gault equation
  • Serum bilirubin =< 1.5 x upper limit of normal (ULN)
  • Aspartate transaminase (aspartate aminotransferase [AST]) or alanine transaminase (alanine aminotransferase [ALT]) =< 2.5 x ULN
  • Alkaline phosphatase =< 2.5 x upper limit (UL)
  • No active bleeding
  • No uncontrolled graft versus host disease (GVHD)
  • No clinical evidence of life-threatening infection
  • Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent
  • Human immunodeficiency virus (HIV) negative and hepatitis B surface antigen (HBs-Ag) negative
  • Negative serum or urine pregnancy test for women with reproductive potential; the only subjects who will be exempt from this criterion are postmenopausal women (defined as women who have been amenorrheic for > 12 months) or subjects who have been surgically sterilized or otherwise proven sterile

Exclusion Criteria:

  • Use of any anti-leukemic agents after relapse is documented (note that the use of these anti-leukemic agents given as post-transplant maintenance therapy is allowed in this study, e.g., subcutaneous or oral 5-azacytidine or FLT3 inhibitors for maintenance) for cohorts 1 and 2
  • Bone marrow blast count > 60% for cohort 1
  • Use of any of the following after transplantation and prior to starting study therapy for cohort 3:

    • Investigational agents/therapies
    • Anti-leukemic agents given as post-transplant maintenance therapy (e.g., subcutaneous or oral 5-azacytidine or FLT3 inhibitors for maintenance)
  • Active acute graft versus host disease (GVHD) grade II or higher
  • Active chronic GVHD that is extensive
  • Concurrent use of systemic immune suppressive other than calcineurin inhibitors and sirolimus
  • Active uncontrolled systemic fungal, bacterial or viral infection
  • Symptomatic or uncontrolled arrhythmias
  • Significant active cardiac disease within the previous 6 months, including: New York Heart Association (NYHA) class III or IV congestive heart failure; unstable angina or angina requiring surgical or medical intervention, and/or; myocardial infarction
  • Known active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)
  • Prior history of solid tumor unless the subject has been free of the disease for >= 1 year; however, subjects with the following history/concurrent conditions are allowed: basal or squamous cell carcinoma of the skin; carcinoma in situ of the cervix; carcinoma in situ of the breast; incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, metastasis [TNM] clinical staging system)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02684162


Contacts
Layout table for location contacts
Contact: Betul Oran, MD 713-792-8750 BOran@mdanderson.org

Locations
Layout table for location information
United States, Texas
M D Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Betul Oran    713-792-8750      
Principal Investigator: Betul Oran         
Sponsors and Collaborators
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Betul Oran M.D. Anderson Cancer Center

Additional Information:
Layout table for additonal information
Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT02684162    
Other Study ID Numbers: 2015-0117
NCI-2016-00343 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
2015-0117 ( Other Identifier: M D Anderson Cancer Center )
P30CA016672 ( U.S. NIH Grant/Contract )
First Posted: February 17, 2016    Key Record Dates
Last Update Posted: December 4, 2019
Last Verified: December 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Preleukemia
Neoplasm, Residual
Myelodysplastic Syndromes
Syndrome
Disease
Pathologic Processes
Neoplasms by Histologic Type
Neoplasms
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Neoplastic Processes
Guadecitabine
Azacitidine
Antineoplastic Agents
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors